Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis

Research output: Contribution to journalReview articlepeer-review


Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury defined by the presence of sclerosis in some (segmental) of certain glomeruli (focal). On electron microscopy, it is characterized by a variable degree of podocyte foot process effacement and gaps in the coverage of the glomerular basement membrane. The pattern of injury occurs when podocytes, highly differentiated cells with limited regenerative capacity, are reduced in number. The heterogeneity in underlying causes of podocyte loss results in equally variable clinical phenotypes. Recent work acknowledging advances in defining the genetic and immunologic basis of disease has redefined the classification of FSGS. Unprecedented clinical trial activity and efficacy of repurposed agents presents hope for improved therapeutic options. This minireview summarizes recent advances with a focus on novel treatment paradigms in FSGS.

Original languageEnglish
Pages (from-to)30-35
Number of pages6
JournalKidney International Reports
Issue number1
StatePublished - Jan 2023


  • FSGS
  • Glomerular Disease
  • Treatment


Dive into the research topics of 'Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis'. Together they form a unique fingerprint.

Cite this